Kris Patel, MD, discusses the real-world data for treatment with ibrutinib in patients with relapsed/refractory mantle cell lymphoma as compared to clinical trials.
Kris Patel, MD, an oncologist at the Swedish Cancer Institute, discusses the real-world data for ibrutinib (Imbruvica) in patients with relapsed/refractory mantle cell lymphoma (MCL) as compared to clinical trials.
Patel says there were 2 major takeaways from these data. First, the overall response and clinical benefit was about the same between the real-world population and the clinical trial results. This shows that the response in the real-world can mirror those in a clinical trial.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More